Pascal Soriot is stuck in a Chinese limbo. In recent months, the CEO of $205 billion drug giant AstraZeneca has seen his ...

In a report released on December 11, David Evans from Kepler Capital maintained a Hold rating on AstraZeneca (AZN – Research Report), with a ...

The AstraZeneca share price is down almost 20% since September! What’s behind this drop, and where do analysts think the ...

We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...

The AstraZeneca PLC ADR AZN slid 0.68% to $66.94 Thursday, on what proved to be an all-around poor trading session for the stock market, with the NASDAQ Composite Index COMP falling 0.66% to 19,902.84 ...

AstraZeneca on Wednesday named Iskra Reic as its new international executive vice president (EVP), taking over from Leon Wang ...

Updated results from the OlympiA Phase 3 trial showed AstraZeneca (AZN) and Merck’s (MRK) Lynparza demonstrated sustained, clinically ...

Shares of AstraZeneca PLC AZN inched up 0.28% to £105.68 Thursday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.12% to 8,311.76.

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

GlobalData’s analysts predict $158 million in global sales for AZD0486 by 2030, with $2.4 billion for Epkinly and $949 ...

AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...